Video summary

Do psychedelics increase or decrease intelligence?

Main summary

Key takeaways

Science and Nature

Scientific Concepts, Discoveries, and Nature/Medical Phenomena

Psychedelics and “Intelligence” (Cognitive Performance)

  • The video frames intelligence as a multi-component brain function, including:
    • memory
    • processing speed
    • executive functioning
    • creativity
    • cognitive flexibility / out-of-the-box thinking
    • attention control
    • working memory
    • emotional processing / social cognition
  • Key idea: mental illness (especially depression) can “hijack” cognition, lowering markers associated with intelligence. Successful treatment may restore cognition.

Depression/PTSD and Cognitive Effects

  • Major depressive episodes can cause a “permanent IQ hit” (as claimed by a professor the speaker cites from medical training).
  • Depression-related cognitive disruption affects:
    • perspective
    • creativity
    • executive functioning
  • Ketamine is discussed as potentially reducing these symptoms rapidly, which may secondarily improve cognition.

Ketamine (Not Classified as a “Classic Psychedelic,” But Legal in the US)

Use History

  • Used for over 50 years
  • Originally developed as anesthesia
  • Later adopted for:
    • mental health (depression, anxiety, PTSD)
    • chronic pain

Mechanistic Theme

  • Emphasis on changes in neural connections and neuroplasticity
  • Potential improvements in:
    • cold cognition (cognitive processes independent of emotion)
    • hot cognition (cognition involving emotional salience/reward learning/social perception)

Procognitive vs Antidepressant Effects (Distinction)

  • The video claims procognitive effects may occur independently of antidepressant effects, based on referenced research.

Claimed Outcomes

  • improved memory and processing speed
  • improved attention clarity (“out of the fog” / “see clearly” in patient anecdotes)

Clinical/Personal Use Mentions

  • The speaker uses IV ketamine clinically
  • Elon Musk is cited as publicly discussing ketamine use

LSD

Historical Origin

  • Albert Hofmann synthesized LSD in 1938
  • The video also reportedly claims Hofmann contacted Steve Jobs in 2007 to support LSD research

Microdosing (“Microdoing”)

  • Popular described in San Francisco and the broader US
  • Claimed to be generally safe
  • Reportedly does not show significant improvements in mood or cognition
  • At least short-term: decreased attention lapses

Higher Doses

  • May produce stronger visual and creativity effects
  • Potential tradeoff:
    • increased distractability
    • decreased working memory

Neurobiology Claim

  • LSD and other psychedelics induce a neuroplastic state linked to cognitive flexibility, modulated by dopamine

Anecdotal Mentions

  • Steve Jobs is cited as saying LSD was one of the most important things he did
  • Gates is mentioned indirectly

Psilocybin (“Magic Mushrooms”)

Historical Reporting

  • Hallucinogenic mushrooms described as early as 1529 by Bernardino de Sahagún (auto-subtitle spelling varies)

Key Discovery (Modern Chemistry)

  • Albert Hofmann isolated psilocybin and psilocin in 1958
  • In the body, psilocybin is ingested and converted to psilocin

Evidence Summary (As Presented)

  • In healthy adults, psilocybin generally shows no clear improvement in cognitive functioning or processing speed
  • Some studies report improvements in:
    • attention control
    • memory
    • executive function
    • emotional processing
    • emotional empathy

Treatment-Resistant Depression Subgroup

  • Procognitive/emotion-related benefits appear more strongly in treatment-resistant depression
  • This suggests antidepressant effects may drive cognition gains

Creativity (“Creative Cognition”)

  • Reportedly improves in some studies but not all

Unknowns

  • Still “a lot to learn,” especially long-term effects

Legality

  • Described as largely illegal in the US

MDMA

Background/Use

  • Patented in 1914 (the subtitle includes “MC”)
  • Historically used as an aid in relationship therapy

Regulatory Status Claim

  • Nearly approved for PTSD in the US in 2024
  • The video alleges the FDA rejected it at the last minute

Proposed Cognitive Pathway

  • Expected to increase empathy and social connection
  • May reduce PTSD severity, potentially improving cognition indirectly

Neurotoxicity Concern

  • Described as toxic to neurons with excessive/recreational use
  • Dysfunctional serotonin signaling is cited as a mechanism potentially causing:
    • memory deficits
    • executive functioning deficits
  • Dose-dependent effects: more use → more deficits

Abstinence

  • Some studies report memory recovery after stopping; others do not
  • Executive deficits may remain

Medical/Supervised Use Claim

  • When medically supervised with smaller doses and less frequent administration, negative side effects appear less likely

DMT + MAO Inhibitors (Ayahuasca)

Cultural and Historical Usage

  • Used in South America for centuries

Synergy Mechanism

  • Contains DMT (psychedelic)
  • Includes MAO inhibitors that prevent DMT breakdown in the body
  • Together enable the oral/ceremonial effect (described as “deep psychedelic/spiritual awakening”)

Evidence Level

  • Highly limited
  • Ritual users:
    • show potential improvements in working memory
    • reportedly show no evidence of long-term cognitive decline
    • an earlier study reportedly found improved thinking style alongside mood/affect and improved quality of life

Legality

  • Still described as illegal in the US

Mescaline (Peyote)

Ceremonial History

  • Longstanding use by Indigenous North American traditions

Natural History / Age Claim

  • Radiocarbon dating suggests peyote use as early as ~5700 years ago

Chemical Discovery

  • Mescaline chemically isolated in 1896 by Arthur Heffter

Potency Note (As Stated)

  • Historical potency lower (~2.25%) vs modern formulations (~8%)

Evidence Level

  • Very limited
  • Experiences from Navajo users (per the video) reportedly show no long-term cognitive deficits with ritual use

Additional Concern

  • Peyote described as endangered
  • Legality issues persist

Methodologies / Frameworks Mentioned (As Outlined in the Video)

  • Clinical interview approach (ketamine):
    • ask patients many questions about:
      • mood improvement
      • cognitive performance
      • mental clarity
    • track changes throughout therapy
  • Cognition categorization:
    • Cold cognition = cognitive processes without emotional involvement
    • Hot cognition = cognition with emotional salience (e.g., reward learning, social perception)
  • Treatment-effect vs drug-effect distinction:
    • whether procognitive effects occur independently of antidepressant/PTSD symptom relief

Researchers or Sources Featured (Explicitly Mentioned)

  • Dr. Anthony Cave (speaker; clinician and researcher/medical provider)
  • Elon Musk (public anecdotal source)
  • Steve Jobs (public anecdotal source)
  • Dr. Albert Hofmann (LSD synthesis; also isolated psilocybin/psilocin; also associated with contacting Jobs)
  • Bernardino de Sahagún (historical recorder of hallucinogenic mushrooms, cited for 1529)
  • Arthur Heffter (chemical isolation of mescaline in 1896)
  • FDA (regulatory body mentioned regarding MDMA approval timeline)
  • Justin Bieber (public anecdotal source re: MDMA/psychedelic experiences; included as an example in the video)

Rate this summary

Your feedback will help improve summaries.

Improve this summary

Reprocess with a stronger model when the summary feels incomplete or inaccurate.

Pro

Translate summary in another language

Pro

Ask questions to this video

Chat for follow-up questions, clarifications, and source-backed answers.

Coming soon

Share this summary

Original video